Metabolism of oxazaphosphorines

Pharmacology and Therapeutics

Volumn 37, Issue 3, 1988, Pages 301-355

  Sladek, N E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DISULFIRAM; IFOSFAMIDE; MELPHALAN; TROFOSFAMIDE; URAMUSTINE;

CANCER CHEMOTHERAPY; DRUG METABOLISM; HUMAN; NONHUMAN; PHARMACOKINETICS; PHARMACOLOGY; REVIEW;

ANIMAL; CELLS; CYCLOPHOSPHAMIDE; HUMAN; IFOSFAMIDE; LETHAL DOSE 50; PHOSPHORAMIDE MUSTARDS;

EID: 0023945947     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(88)90004-6     Document Type: Article

References (330)

1. Comparative study of erythrocyte aldehyde dehydrogenase in alcoholics and control subjects
2. Formation of the cytotoxic aldehyde acrolein during in vitro degradation of cyclophosphamide
3. Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide
4. The effect of phenobarbital on cyclophosphamide antitumor activity
5. Mouse mitochondrial aldehyde dehydrogenase isozymes: Purification and molecular properties
6. Liver cytosolic aldehyde dehydrogenases from “alcohol-drinking” and “alcohol-avoiding” mouse strains: Purification and molecular properties
7. In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes
8. Pharmacokinetics of ifosfamide
9. Human pharmacokinetic model for isophosphamide (NSC-109724)
10. Drug metabolism in normal children, lead-poisoned children, and normal adults
11. Antineoplastic agents
12. Antineoplastic agents
13. Antineoplastic agents
14. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma
15. Synthese und abbau cytostatisch wirksamer cyclischer N-phosphamidester des bis-(β-chloräthyl)-amins
16. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat
17. Über beziehungen zwischen chemischer konstitution und cancertoxischer wirkung in der reihe der phosphamidester de bis-(β-chloräthyl)-amins
18. Clinical pharmacology of cyclophosphamide
19. Characterization of the major sheep urinary metabolites of cyclophosphamide, a defleecing chemical
20. Metabolism of cyclophosphamide by sheep
21. Effect of treatment on the evolution of renal abnormalities in lupus nephritis
22. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination
23. Enzymatic toxicogenation of “activated” cyclophosphamide by 3′-5′ exonucleases
24. Activated cyclophosphamide: An enzyme-mechanism-based suicide inactivator of DNA polymerase/3′-5′ exonuclease
25. Base-catalyzed hydrolysis of 4-hydroperoxycyclophosphamide: Evidence for iminocyclophosphamide as an intermediate
26. The mechanism of activation of 4-hydroxycyclophosphamide
27. 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution
28. 31P Nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites
29. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. 2. Direct observation, characterization, and reactivity studies of iminocyclophosphamide and related species
30. The disposition of cyclophosphamide in a group of myeloma patients
31. A comparative study of the inhibition of hepatic aldehyde dehydrogenases in the rat by methyltetrazolethiol, calcium carbimide, and disulfiram
32. Pharmacologic characterization of cyclophosphamide (NSC-26271) and cyclophosphamide metabolites
33. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds
34. The special position of ifosfamide in the series of cytostatically active oxazaphosphorines
35. Oxazaphosphorine cytostatics: Structure-activity relationships, selectivity and metabolism, regional detoxification
36. Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics
37. Über die aktivierung von cyclophosphamid in vivo und in vitro
38. Metabolism of cyclophosphamide
39. The problem of specificity and selectivity of alkylating cytostatics: Studies on N-2-chloroethylamido-oxazaphosphorines
40. DNA crosslinking by 4-hydroperoxycyclophosphamide in sensitive and resistant mouse leukemia cells
41. Chemotherapy of neoplastic diseases
42. The effect of various aldehydes on the respiration of rat liver and hepatoma AH-130 cells
43. Cyclophosphamide potentiation and aldehyde oxidase inhibition by phosphorylated aldehydes and acetals
44. Role of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: Critical review of syngeneic, autologous, and allogeneic transplants
45. Analysis and excision of ring-opened phosphoramide mustard-deoxyguanine adducts in DNA
46. Phosphorylation of 2-d-deoxyglucose and associated inorganic phosphate uptake in ascites tumor cells
47. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat
48. Pharmacokinetics of cyclophosphamide in man
49. The comparative pharmacology of cyclophamide and ifosfamide
50. Pharmacology of cyclophosphamide and metabolites
51. Alkylating properties of phosphoramide mustard
52. A biologically active metabolite of cyclophosphamide
53. Pharmacological implications of microsomal enzyme induction
54. Microsomal activation of cyclophosphamide in vivo
55. Observations on the metabolism of cyclophosphamide
56. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide
57. The microsomal metabolism of some analogues of cyclophosphamide: 4-Methylcyclophosphamide and 6-methylcyclophosphamide
58. The enzymatic basis of the selective action of cyclophosphamide
59. Proceedings of the Symposium on the Metabolism and Mechanism of Action of Cyclophosphamide
60. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes
61. Clinical pharmacology of isophosphamide
62. Intracellular localization and properties of aldehyde dehydrogenase from sheep liver
63. Tissue and subcellular distribution of mammalian aldehyde-oxidizing capacity
64. Genetic aspects of increase in rat liver aldehyde dehydrogenase induced by phenobarbital
65. Genetic influence upon phenobarbital-induced increase in rat liver supernatant aldehyde dehydrogenase activity
66. Characteristics of the induction of aldehyde dehydrogenase in rat liver
67. Induction of aldehyde dehydrogenase
68. 14C-cyclophosphamide: Comparative drug metabolism studies on African and American patients with lymphosarcoma and Burkitt's tumor
69. Decreased half life of cyclophosphamide in patients under continual treatment
70. Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients
71. Effect of chloramphenicol on the metabolism and lethality of cyclophosphamide in rats
72. Cyclophosphamide as a chemical “defleecing” agent for sheep
73. Biotransformation of “activated” cyclophosphamide
74. Potential for in vivo inactivation of a cyclophosphamide metabolite (aldophosphamide) by tumor enzymes
75. Kinetics of cyclophosphamide biotransformation in vivo
76. Metabolism of 4-hydroxycyclophosphamide/aldophosphamide in vitro
77. Inhibition by cyanamide of 4-hydroxycyclophosphamide/aldophosphamide oxidation to carboxyphosphamide
78. Pediatric clinical pharmacology and the “therapeutic orphan”
79. Drug metabolism after repeated treatments with cytotoxic agents
80. The effect of cytotoxic agents on drug metabolism
81. Effect of cyclophosphamide on the activity and distribution of pentobarbital in rats
82. Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect
83. Effect of phenobarbital on cyclophosphamide cytotoxic activity and pharmacokinetics in mice
84. Cimetidine enhancement of cyclophosphamide antitumor activity
85. Interaction of cimetidine but not ranitidine with cyclophosphamide in mice
86. Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells
87. Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds
88. Oxidative metabolism of N-isopropyl-α-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine) by rat liver microsomes
89. Detection and partial characterization of a varient form of cytosolic aldehyde dehydrogenase isozyme
90. Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy
91. Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide
92. Cyclophosphamide pharmacokinetics and metabolism after repeated high dose administration in BMT
93. 31P NMR investigations of phosphoramide mustard: Evaluation of pH control over the rate of intramolecular cyclization to an aziridinium ion and the hydrolysis of this reactive alkylator
94. 31P NMR kinetic studies of the intra- and intermolecular alkylation chemistry of phosphoramide mustard and cognate N-phosphorylated derivatives of N,N-bis(2-chloroethyl)amine
95. Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro
96. The biotransformation of cyclophosphamide in man: Influence of prednisone
97. The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man
98. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis
99. Alopecia activity of cyclophosphamide metabolites and related compounds in sheep
100. Identification of phosphorodiamidic acid mustard as a human metabolite of cyclophosphamide
101. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans
102. Iminocyclophosphamide as a chemically reactive metabolite of cyclophosphamide
103. Studies on the mechanism of action of cytoxan—Evidence of activation in vivo and in vitro
104. Effects of cyclophosphamide and of busulfan on spleen conony-forming units and on hematopoietic stroma
105. Studies of some newer phosphoramide mustards
106. Preparation of N-phosphorylated derivatives of bis-β-chloroethylamine
107. Colorimetric estimation of nitrogen mustards in aqueous media. Hydrolytic behavior of bis(beta-chloroethyl)-amine, norHN2
108. Cyclophosphamide (NSC-26271)-related phosphoramide mustards—Recent advances and historical perspective
109. Cyclophosphamide and related phosphoramide mustards. Current status and future prospects
110. Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung
111. The effect of disulfiram on cyclophosphamide-mediated myeloid toxicity
112. Disappearance of phenobarbital and diphenylhydantoin from serum of children
113. Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents
114. Aldehyde oxidation: Ethnic variation in metabolism and response
115. The role of alcohol dehydrogenase and aldehyde dehydrogenase isozymes in alcohol metabolism, alcohol sensitivity, and alcoholism
116. Mechanism of cyclophosphamide transport by L5178Y lymphoblasts in vitro
117. Histochemical demonstration of sites of phosphamidase activity
118. Intensive immunosuppression with cyclophosphamide in multiple sclerosis
119. Autologous bone marrow transplantation using marrow incubated with ASTA Z 7557 in adult acute leukemia
120. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration
121. Clinical pharmacokinetics of cyclophosphamide
122. Studies on the effects of cyclophosphamide, vincristine, and prednisone on some hepatic oxidations and conjugations
123. Effects of the induction of hepatic microsomal metabolism on the toxicity of cyclophosphamide
124. Influence of pretreatment with disulfiram on the acute toxicity of cyclophosphamide in male Sprague-Dawley rats
125. Effect of disulfiram (tetraethylthiuram disulfide) and diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice
126. Electrophoretic and biochemical studies of human aldehyde dehydrogenases in various tissues
127. Effects of systemic acidification of mice with sarcoma 180
128. Effect of microsomal enzyme modifiers on toxicity and therapeutic activity of cyclophosphamide in mice
129. Effects of the lipid peroxidation product 4-hydroxynonenal and related aldehydes on proliferation and viability of cultured Ehrlich ascites tumor cells
130. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH
131. Cellular distribution and properties of human blood aldehyde dehydrogenase
132. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vitro in mice
133. Immunodulation by cyclophosphamide
134. 14C]aminopyrine
135. Abnormal aminopyrine metabolism in patients with hepatic neoplasm
136. Microsomal enzymes in patients with gastric carcinoma as determined by plasma half-life of antipyrine
137. Antipyrine metabolism in cancer patients
138. Oxazaphosphorines as biological response modifiers—Experimental and clinical perspectives
139. Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite
140. Metabolism of iphosphamide [2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide] and production of a toxic iphosphamide metabolite
141. Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells
142. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia
143. The role of aldehyde dehydrogenase activity in cyclophosphamide sensitivity of hematopoetic and leukemic cell populations
144. Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide
145. 4-Ketocyclophosphamide, a metabolite of cyclophosphamide. Formation, chemical and biological properties
146. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity
147. Release of phosphoramide mustard from activated cyclophosphamide by DNA-polymerase linked 3′5′-exonuclease as basis for cytotoxic specificity
148. The enzymatic basis of cyclophosphamide specificity
149. Intermittent cyclophosphamide in refractory rheumatoid arthritis
150. Tumor-selective modification of cellular microenvironment in vivo: Effect of glucose infusion on the pH in normal and malignant rat tissues
151. Phenobarbital effects on cyclophosphamide pharmacokinetics in man
152. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy
153. Comparative metabolism of 2-[bis(2-chloroethyl)-amino]tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans
154. Effects of elevated female sex steroids on ethanol and acetaldehyde metabolism in humans
155. Immunosuppression with azathioprine, prednisone, and cyclophosphamide
156. Pharmacokinetics of cyclophosphamide in Kenyan Africans
157. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration
158. The kinetics of salivary elimination of cyclophosphamide in man
159. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy
160. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites
161. Pharmacokinetics of cyclophosphamide in Kenyan African children with lymphoma
162. Pharmacodynamics of chemotherapeutic effects: Dose-time-response relationships for phase-nonspecific agents
163. Alkylation of guanosine by phosphoramide mustard, chloromethine hydrochloride and chlorambucil
164. Drug metabolism under pathological and abnormal physiological states in animals and man
165. The effect of 5,5′-dithiobis(1-methyltetrazole) on cytoplasmic aldehyde dehydrogenase and its implications for cephalosporin-alcohol reactions
166. In vitro chemotherapy with ASTA-Z-7557: Studies in rat and human acute myeloid leukemia
167. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines
168. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557)
169. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines
170. Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557)
171. Different forms of rat liver aldehyde dehydrogenase and their subcellular distribution
172. Partial purification and properties of a phenobarbital-induced aldehyde dehydrogenase of rat liver
173. 4-Hydroperoxycyclophosphamide: A model for eliminating residual human tumour cells and T-lymphocytes from bone marrow graft
174. Enhancement of aldehyde dehydrogenase activity in rat liver by clofibrate feeding
175. Activation mechanisms of mafosfamide and role of thiols in cyclophosphamide metabolism
176. Spectroscopic detection of iminocyclophosphamide and its possible role in cyclophosphamide metabolism
177. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin
178. Effects of disulfiram and three related compounds on the activity of alcohol dehydrogenase and aldehyde dehydrogenase in rat liver and gastric mucosa
179. Zur frage der permeabilität von N,N-bis(2-chloräthyl)phosphorsäurediamid in tumorzellen
180. Nuclear magnetic resonance study of stability of a salt of N,N-bis(2-chloroethyl)phosphorodiamidic acid (NSC-69945) in aqueous solution
181. Regulation of aldehyde dehydrogenase activity in five rat hepatoma cell lines
182. Induction of aldehyde dehydrogenase during hepatocarcinogenesis
183. Some interactions of nitrogen mustards with constituents of human blood serum
184. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysts
185. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers
186. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologus bone marrow rescue
187. Synthesis of reactive metabolite-analogues of cyclophosphamide for comparisons of NMR kinetic parameters and anticancer screening data
188. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of “phenylketophosphamide” and similar compounds related to the cyclophosphamide metabolite aldophosphamide
189. Primary evaluation of alkylating agent cyclohexylamine salt of N,N-bis(2-chloroethyl)phosphorodiamidic acid (NSC 69945; OMF-59) in experimental antitumor assay systems
190. Cytotoxic activity of mafosfamide against tumor and hematopoietic stem cells in the presence and absence of chloral hydrate
191. In vitro active cyclophosphamide derivatives in cleansing procedures intended for autologous bone marrow transplantation
192. Significance of stimulation and inhibition of drug metabolism in pharmacological testing
193. Characterization of NAD-linked aldehyde dehydrogenase catalysis of the oxidation of aldophosphamide by mouse liver fractions
194. Some modern aspects of systemic lupus erythematosus with special reference to the treatment with cyclophosphamide of lupus nephropathy
195. Comparison of phenobarbital- and carcinogen-induced aldehyde dehydrogenases in the rat
196. Tumor viruses and the kinase connection
197. Drug resistance of cancer cells probed
198. Biochemical genetics of aldehyde dehydrogenase isozymes in the mouse: Evidence for stomach- and testis-specific enzymes
199. Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine
200. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma
201. Alkylation of guanosine and deoxyguanosine by phosphoramide mustard
202. Activation of cyclophosphamide metabolism in various species
203. Metabolism of high doses of cyclophosphamide
204. The relationship of the metabolism of anticancer agents to their activity
205. Synthesis and structure-activity relationships of pre-activated analogs of cyclophosphamide (NSC-26271)
206. Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy
207. Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma
208. The biotransformation of cyclophosphamide in man: Analysis of the variation in normal subjects
209. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide
210. Combined prednisolone, azathioprine, and cyclophosphamide treatment for persistent proliferative glomerulonephritis in adults
211. Synthesis of aldophosphamide, a key cyclophosphamide metabolite
212. Genetic control of responsiveness of rat liver supernatant aldehyde dehydrogenase to phenobarbital and 3-methylcholanthrene
213. Clinical toxicologic study of cyclohexylamine salt of N,N-bis(2-chlorethyl)phosphorodiamidic acid (NSC-69945; OMF-59)
214. Developmental aspects of the hepatic cytochrome P450 monooxygenase system
215. Pharmacokinetics of divided-dose ifosfamide
216. Chemical characterization of ASTA Z 7557 (INN mafosfamide, cis-4-sulfoethylthiocyclophosphamide), a stable derivative of 4-hydroxycyclophosphamide
217. Studies on the metabolism of isophosphamide (NSC-109724) in man
218. Untersuchungen an hypothetischen metaboliten des 2-[bis(2-chloräthyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxids (cyclophosphamide)
219. New promise for autologous marrow transplants in leukemia
220. Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens
221. Subcellular distribution and properties of a clofibrate-induced aldehyde dehydrogenase from rat liver
222. Metabolism of polycyclic aromatic hydrocarbons: Etiologic role in carcinogenesis
223. Carcinostatic effect of aliphatic aldehydes and aldehyde dehydrogenase activity in Ehrlich carcinoma, Sarcoma 180, and Yoshida AH 130 hepatoma
224. Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides
225. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): A simple preparation method and its application for the synthesis of a new class of “activated” sulfur-containing cyclophosphamide (NSC-26271) derivatives
226. Role of liver cytosolic aldehyde dehydrogenase isozymes in control of blood acetaldehyde concentrations
227. Pharmacokinetic studies in lung cancer patients
228. Aldehyde dehydrogenase isozymes
229. Intracellular pH of the Ehrlich ascites tumor cell as it is affected by sugar and sugar derivatives
230. Effects of inhibitors of glycolysis on intracellular pH and on accumulation of glycolytic intermediates in the Ehrlich ascites tumor cell
231. Intracellular pH of the Ehrlich ascites tumor cell
232. Circulating phosphoramide mustard and the pharmacologic action of cyclophosphamide
233. Influence of thiosulfate on the cytotoxic action of cyclophosphamide metabolites
234. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats
235. Phase II trial of ifosfamide in children with malignant solid tumors
236. Bioenergetics and the problem of tumor growth
237. Differential cytotoxicity and DNA cross-linking produced by polymeric and monomeric activated analogues of cyclophosphamide in mouse L1210 leukemia cells
238. Total lymphoid irradiation and cyclophosphamide as preparation for bone marrow transplantation in severe aplastic anemia
239. Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemia
240. Der gesamtalkylantien-blutspiegel von ratten nach verabreichung von cyclophosphamid und acyclophosphamid
241. Induction of liver acetaldehyde dehydrogenase: Possible role in ethanol tolerance after exposure to barbiturates
242. The cellular uptake of 4-hydroperoxycyclophosphamide
243. 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin
244. Salivary elimination of cyclophosphamide in man
245. Adoptive immunotherapy of cancer: Accomplishments and prospects
246. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
247. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
248. Isoelectric focusing studies of aldehyde dehydrogenases from mouse tissues: Variant phenotypes of liver, stomach and testis isozymes
249. Toxicity in mice of new secondary nitrogen mustards
250. Establishment of cross-resistance profiles for new agents
251. Formation and properties of reactive aldehydes
252. Intracellular pH and buffering capacity of the Walker 256 carcinoma
253. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and l-phenylalanine mustard
254. Development of new methods for the histochemical demonstration of hydrolytic intracellular enzymes in a program of cancer research
255. Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphoramide mustard on murine hematopoietic and immunocompetent cells
256. The capacity of microsomally-activated cyclophosphamide to induce immunosuppression in vitro
257. Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide
258. Development of cyclophosphamide activation and its implications in perinatal toxicity to mice
259. Fetal and neonatal development of the microsomal monooxygenase system
260. Aldehyde dehydrogenases in rat liver
261. Human liver dehydrogenase. Kinetics of aldehyde oxidation
262. Inorganic phosphate in Ehrlich ascites tumor cells and its distribution across the cell membrane
263. Metabolism of cyclophosphamide by rat hepatic microsomes
264. Therapeutic efficacy of cyclophosphamide as a function of its metabolism
265. Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism
266. Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide
267. Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo
268. Potentiation of the cytotoxic action of melphalan and “activated” cyclophosphamide against tumor cells growing in vitro by centrophenoxine
269. Potentiation of antitumor drug action by centrophenoxine: Specificity
270. Cytotoxic activity of alkylating agents in the presence of centrophenoxine and its hydrolysis products
271. Oxazaphosphorines
272. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines
273. Differential effects of Walker 256 carcinosarcoma cells growing subcutaneously, intramuscularly, or intraperitoneally on hepatic microsomal mixed-function oxygenase activity
274. Plasma half-life and urinary excretion of cyclophosphamide in pediatric patients
275. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity
276. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation
277. Half-life of oxazaphosphorines in biological fluids
278. Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines
279. Sensitivity of murine B- and T-lymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustards
280. The role of liver cytosolic aldehyde dehydrogenase in ethanol metabolism in DBA and C57B1 mice
281. Cyclophosphamide and whole organ transplantation in human beings
282. Cyclophosphamide and its congeners
283. Isolation and identification of a stabilized derivative of aldophosphamide, a major metabolite of cyclophosphamide
284. Aldophosphamide: Synthesis, characterization, and comparison with “Hohorst's aldophophamide”
285. Urinary metabolites of the antitumor agent cyclophosphamide
286. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: Evidence for phosphoramide mustard as the biologically active metabolite
287. Synthesis and antitumor evaluation of isophosphoramide mustard, the active metabolite of the clinical antitumor agent ifosfamide
288. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide
289. Cross-linking of DNA in L1210 cells and nuclei treated with cyclophosphamide and phosphoramide mustard
290. Studies on cyclophosphamide metabolites and their related compounds
291. Studies on cyclophosphamide metabolites and their related compounds. Preparation of an active species of cyclophosphamide and related compounds
292. Inhibition of hepatic microsomal enzymes by alkylating agents
293. Alkylating agents: In vitro studies of cross-resistance patterns in human cell lines
294. Bone-marrow transplantation
295. Bone-marrow transplantation
296. Genetics and ontogeny of aldehyde dehydrogenase isozymes in the mouse: Evidence for a locus controlling the inducibility of the liver microsomal isozyme
297. The metabolic fate of cyclophosphamide
298. Induction of aldehyde dehydrogenase by polycyclic aromatic hydrocarbons in rats
299. Metabolic disposition of antipyrine in patients with lung cancer
300. Disulfiram-like reaction to certain cephalosporins
301. 4-Hydroperoxidation in the Fenton oxidation of the antitumor agent cyclophosphamide
302. Genetic and environmental factors affecting drug disposition in man
303. Die pharmakokinetik von cyclophosphamid und cyclophosphamid-metaboliten bei der maus und ihr einfluß auf die therapeutische wirkung von “aktiviertem” cyclophosphamid (4-hydroxycyclophosphamid)
304. Identification and pharmacokinetics of cyclophosphamide (NSC 26271) metabolites in vivo
305. Evidence for enzymatic toxification of activated cyclophosphamide (4-hydroxycyclophosphamide)
306. Studien zum spontanzerfall von 4-hydroxycyclophosphamid und 4-hydroperoxycyclophosphamid mit hilfe der dünnschichtchromatographie
307. Proceedings of the Symposium on the New Oxazaphosphorine, ASTA Z 7557
308. Identification of three alkylated nucleotide adducts from the reaction of guanosine 5′-monophosphate with phosphoramide mustard
309. Intracellular pH
310. Bioavailability of cyclophosphamide from oral formulations
311. Pharmacokinetics and bioavailability of oral ifosfamide
312. Einfluß von leberparenchymschäden, niereninsuffizienz und hämodialyse auf die pharmakokinetik von cyclophosphamid und seinen aktiviertem metaboliten
313. Über blutspiegel und urin-ausscheidung von aktiviertem cyclophosphamid und seinen deaktivierungsprodukten beim menschen
314. Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test
315. Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemia
316. Enzymology of carbonyl metabolism: Aldehyde dehydrogenase and aldo/keto reductase
317. Enzymology of carbonyl metabolism: Aldehyde dehydrogenase and aldo/keto reductase
318. Metabolic activation of procarbazine
319. Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma
320. Does acrolein contribute to the cytotoxicity of cyclophosphamide?
321. Effects of cephem antibiotics on rat liver aldehyde dehydrogenases
322. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide
323. Immunological concepts and the combination of cyclophosphamide with 5-aza-2′-deoxycytidine on L1210 in vivo
324. Cyclophosphamide analogues
325. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the conconmitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways